eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
Clinical research

Mean platelet volume changes before and after glycated hemoglobin (HbA1c) improvement in a large study population

Yasar Sertbas, Meltem Sertbas, Nalan Okuroglu, Mehmet Akif Ozturk, Kerem Yigit Abacar, Ali Ozdemir

Arch Med Sci 2017; 13, 4: 711–715
Article file
- mean platelet.pdf  [0.08 MB]


Diabetes mellitus (DM) is a real worldwide problem with increasing prevalence in daily practice [1]. It is a metabolic disorder characterized by hyperglycemia associated with both microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (ischemic heart disease, peripheral vascular disease, and cerebrovascular disease) complications resulting in organ and tissue damage [2, 3].
Increased platelet activity plays a major role in the development of vascular complications in DM [4]. Although there are several measurements to show the platelet activity (platelet aggregometry, platelet surface p-selectin, platelet surface-activated glycoprotein IIb/IIIa, platelet function analyzer-100, serum thromboxane B2, and urinary 11-dehydro-thromboxane B2), almost all of these measurements are time-consuming, expensive or they require special training [5–7]. Mean platelet volume (MPV) is an alternative marker for platelet activity. It can be determined on routine automated hemograms as part of the whole blood count, with a relatively low cost [6–8]. Higher MPV values indicate larger platelets, which are metabolically and enzymatically more active, with a greater prothrombotic potential [8–10].
There are many studies on the comparison of MPV between diabetics and non-diabetic controls. Since patients with diabetes mellitus have many other metabolic disorders such as hyperlipidemia, hypertension, coronary and cerebrovascular diseases which can change the MPV levels independently, it is not surprising to find the MPV levels higher in diabetic patients than healthy controls [11–16]. On the other hand, there are few studies with small study populations comparing MPV levels before and after the treatment of diabetes mellitus [17–19]. The aim of this study is to compare the MPV levels before and after the decrease of glycated hemoglobin (HbA1c) in a large diabetic population and to assess the relationship of MPV with HbA1c, fasting blood glucose and postprandial glucose levels.

Material and methods

This was a retrospective study conducted on type 2 diabetic patients from the outpatient clinic at the department of internal medicine between January 2014 and February 2015. During the 1-year period, the levels of HbA1c and other biochemical markers of 10 038 diabetic patients were determined. After the evaluation of these records, 595 patients were recruited into the study. The main inclusion criteria of recruitment were to be examined in outpatient clinics at least twice a year with full laboratory parameters including HbA1c with whole blood count and having a decrease of HbA1c of at least 0.5% during these treatment periods. Participants with no satisfactory decrease of glucose levels, who had any infection, type 1 DM, thrombotic or hematologic disorders, any medication affecting platelet function, hemoglobin (Hb) < 12.5 g/l in men and < 11.5 g/l in women were excluded from the study. Approval for this study was obtained from the ethics committee of the Fatih Sultan Mehmet Education and Research Hospital.
The MPV was analyzed by an automated blood counter (Cell Dyne 3700, Abbot Diagnostic) with the impedance flow cytometric method. Glucose level measurements were carried out by the (fasting and postprandial plasma glucose) glucose oxidase method in the autoanalyzer (Architect C16000, Abbot Diagnostic), and the HbA1c level was measured by the automated high-performance liquid chromatography method.

Statistical analysis

All analyses were performed using Statistical Package for the Social Sciences (SPSS) version 22.0 for Windows. Data are expressed as mean  standard deviation. The one-sample Kolmogorov-Smirnov test was performed to assess the distribution of data. Numerical variables in different subjects were compared by the t-test or Mann-Whitney U test. Comparison of variables before and after the treatment were compared by the paired t-test or Wilcoxon test. Bivariate correlation analyses were performed using the Pearson correlation test. Categorical variables were analyzed by the 2 test. Probability values were two tailed, and a p-value of less than 0.05 was considered significant.


In this study the 595 participants included 334 female and 261 male diabetics with a mean age of 58.99 11.65 years and duration of DM was 9.93 7.09 years. During the follow-up period (4.51 1.39 months), the mean HbA1c decrease was 1.96 1.43%. There were significant changes in the MPV levels, platelet count, HbA1c, fasting blood glucose and postprandial glucose levels after the treatment of diabetes (Table I).
When we compared the mean difference of MPV and HbA1c changes before and after the treatment, we found a positive correlation between the two parameters (∆MPV = 0.93 0.96 vs. ∆HbA1c = 1.96 1.43; p = 0.005, r = 0.115).
Although there were significant differences in MPV levels before and after the decrease of glucose levels, we did not find any significant correlation between basal MPV levels and other parameters except platelet count, which showed a significant negative correlation (Table II). In linear regression analysis, the relation of MPV and platelet count was as follows: 95% confidence interval (CI): (–0.009)–(–0.005), constant: 10.948, unstandardized  = –0.007, p < 0.001.
The participants were divided into two groups according to their basal HbA1c levels (group A (n = 50 patients): HbA1c ≤ 6.5% and group B (n = 545 patients): HbA1c > 6.5%) and compared with each other. HbA1c, fasting blood glucose (FBG), and postprandial glucose (PPG) were higher in group A than group B, as expected. Platelet count was lower in group A than B. There was no significant difference in MPV value between groups A and B (Table III).
We also compared each group before and after the improvement of glucose levels. It was found that the further decrease of HbA1c in group A could still provide a significant decrease of MPV (Tables IV, V).
When we investigated the correlation of the mean difference of MPV and HbA1c changes in groups A and B before and after the treatment, although there was a positive correlation for group B, we did not find any correlation for group A (group A: ∆MPV = 0.98 0.91 vs. ∆HbA1c = 0.67 0.23; p = 0.118, r = 0.224) (group B: ∆MPV = 0.93 0.97 vs. ∆HbA1c = 2.08 1.45; p = 0.005, r = 0.120).
When we categorize the patients according to their treatment modalities as oral anti-diabetic or insulin usage, basal MPV levels were significantly higher than post-treatment MPV levels after the glycemic improvement for both groups (Table VI). There were also no significant differences in MPV levels between oral antidiabetic drugs (OAD) and insulin using patients before and after glycemic improvement (p = 0.081 and p = 0.379).


Platelet hyperactivity has been reported in the literature and supported by numerous studies in diabetic patients [3, 20–22]. On the other hand, it is also known that platelet hyperactivity in patients with diabetes is multifactorial and associated with biochemical factors such as hyperglycemia, hyperlipidemia, insulin resistance, and inflammatory and antioxidant states [23]. Since it is not clear if the increased platelet activity is just due to hyperglycemia or due to associated diseases and biochemical factors, case-control studies may not reflect the real situation. Although there are many studies comparing the platelet activity of diabetics with controls with up to 1558 recruits, there are few investigations, with only a small number of participants, comparing the pre- and post-treatment values of platelet activity. Our study is one of the largest studies comparing pre- and post-treatment values of MPV, with a population of 595.
The MPV is a parameter of platelet size and is easily determined by routine automated hemograms. It is a potential marker of platelet reactivity with the correlation of platelet function and activity measured as aggregation, thromboxane synthesis, and B-thromboglobulin release [24]. It has been shown that larger platelets are more active and have greater prothrombotic potential than smaller platelets [8, 25]. Osmotic swelling due to increased blood glucose and metabolites has been suggested as a possible mechanism for increased MPV [26].
In two of the studies, with 60 and 70 diabetic subjects, MPV levels were significantly decreased with the improvement of glycemic control [16, 17]. In our study mean platelet volumes of participants were significantly decreased with glycemic control (9.11 1.42 vs. 8.17 1.04), as in the literature.
Although there are several studies showing a relationship between MPV and some of the glycemic indices, there are also some other studies showing no correlation between these parameters, as shown in Table VII [18, 20–22, 27, 28]. In our study, we found no correlation between age, DM duration, FBG, and PPG. The platelet count is the only parameter showing a negative correlation with MPV, in line with the studies of Dindar and Kei et al. [25, 29]. According to Hwang et al., the cause of the inverse relationship between MPV and platelet count is connected to the tendency to maintain hemostasis by preserving a constant platelet mass [28]. We also found a significant positive correlation between ∆MPV and ∆HbA1c levels, and we thought that this correlation is more valuable for showing the importance of glycemic control than comparison of basal MPV levels with other parameters.
Some of the studies divided the patients into two groups with low and high HbA1c levels, and almost all of them found higher MPV levels in the group with poor glycemic control [20, 27]. In our study, although MPV levels were higher in diabetics with HbA1c levels > 6.5% than the group with HbA1c levels ≤ 6.5%, the difference was not statistically significant. We thought that this condition might be due to the patients’ comorbid diseases that can influence the MPV levels. Then we also evaluated the subgroups before and after the glycemic recovery. We found that basal MPV levels were significantly lower than the levels after the glycemic control for both groups. Our study may be the first one to show that improvement of basal HbA1c levels below 6.5% can still continue to provide a significant decrease of MPV levels. Although there was a positive correlation between ∆MPV and ∆HbA1c levels for group B (HbA1c > 6.5%), we did not find any correlation for group A (HbA1c < 6.5%). We thought that this difference might be due to the lower number of participants in group A (n = 50) than group A (n = 545).
Insulin can directly regulate platelet function via the functional insulin receptor (IR) found on healthy human platelets [30]. The effects of hyperinsulinemia on platelets are complex and disparate between normal individuals and patients with insulin resistance. Indeed, insulin therapy in patients with type 2 DM may lead to paradoxical increases in platelet reactivity in vivo [31]. We also compared the MPV of the diabetics, according to their treatment regimens as only oral antidiabetic usage or insulin usage. There was no significant difference of MPV levels between the insulin and OAD users. On the other hand, after the decrease of HbA1c levels, MPV values decreased significantly in both groups.
This study has some limitations. Firstly, this is a retrospective study. Secondly, patients were not categorized according to diabetic complications. Thirdly, oral and parenteral antidiabetic drugs used are not classified separately. Also, exercise status in the study period is unknown. Finally, the findings are limited to the data taken in the outpatient clinics during the visits of the patients.
In conclusion, the results of this study show that better glycemic control is associated with a significant decrease of MPV levels, regardless of whether the treatment modality is insulin or oral antidiabetic.

Conflict of interest

The authors declare no conflict of interest.


1. Erem C, Kuzu UB, Deger O, Can G. Prevalence of gestational diabetes mellitus and associated risk factors in Turkish women: the Trabzon GDM Study. Arch Med Sci 2015; 11: 724-35.
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
3. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 2004; 116: 11-22.
4. Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol 2011; 2011: 742719.
5. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103: 20-6.
6. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998; 135: 170-8.
7. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181-8.
8. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 148-56.
9. Hekimsoy Z, Payzin B, Ornek T, Kandoğan G. Mean platelet volume in type 2 diabetic patients. J Diabetes Complications 2004; 18: 173-6.
10. Yilmaz M, Delibas IB, Isaoglu U, Ingec M, Borekci B, Ulug P. Relationship between mean platelet volume and recurrent miscarriage: a preliminary study. Arch Med Sci 2015; 11: 989-93.
11. Vericel E, Januel C, Carreras M, Moulin P, Lagarde M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 2004; 53: 1046-51.
12. Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Q J Med 1993; 86: 739-42.
13. Davì G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
14. Senaran H, Ileri M, Altınbas A, et al. Thrombopoietin and mean trombosit volume in coronary artery disease. Clin Cardiol 2001; 24: 405-8.
15. Bath P, Algert C, Chapman N, et al. Association of mean trombosit volume with risk of stroke among 3134 individuals with history of cerebrovasculer disease. Stroke 2004; 35: 622-6.
16. Wang Y, Lammi-Keefe CJ, Hou L, Hu G. Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 2013; 102: 65-75.
17. Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications 2009; 23: 89-94.
18. Dolasık I, Sener SY, Celebı K, Aydın ZM, Korkmaz U, Canturk Z. The effect of metformin on mean platelet volume in diabetic patients. Platelets 2013; 24: 118-21.
19. Saigo K, Yasunaga M, Ryo R, Yamaguchi N. Mean platelet volume in diabetics. Rinsho Byori 1992; 40: 215-7.
20. Kodiatte TA, Manikyam UK, Rao SB, et al. Mean platelet volume in type 2 diabetes mellitus. J Lab Physicians 2012; 4: 5-9.
21. Shah B, Sha D, Xie D, Mohler ER, Berger Jl. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health and Nutrition Examination Survey, 1999-2004. Diabetes Care 2012; 35: 1074-8.
22. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009; 32: 525-7.
23. Karpatkin S. Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest 1969; 48: 1073-82.
24. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-61.
25. Dindar S, Cinemre H, Sengul E, Annakkaya AN. Mean platelet volume is associated with glycaemic control and retinopathy in patients with type 2 diabetes mellitus. West Indian Med J 2013; 62: 519-23.
26. Papanas N, Symeonidis G, Maltezos E, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004; 15: 475-8.
27. Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood 1988; 72: 1-8.
28. Hwang DL, Yen CF, Nadler JL. Insulin increases intracellular magnesium transport in human platelets. J Clin Endocrinol Metabol 1993; 76: 549-53.
29. Kei A, Elisaf M. Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia. Arch Med Sci 2014; 10: 439-44.
30. Ferreira IA, Mocking AIM, Feijge MAH, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-22.
31. Angiolillo DJ, Bernardo E, Ramírez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006; 48: 298-304.
Copyright: © 2016 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2017 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe